Blood test may offer early warning of liver cancer recurrence after liver transplant

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA circulating in the bloodstream—may help identify liver cancer recurrence earlier in transplant recipients and reduce the need for invasive procedures, according to a new study from Houston Methodist.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup